Personalized TCR T Cells Enabled by CRISPR

A 16-person trial demonstrated the feasibility and safety of using CRISPR gene editing to create personalized T-cell therapies equipped with neoantigen-specific T-cell receptors. However, the elaborate manufacturing process and limited efficacy of the engineered cells have prompted the therapy’s sponsor to pursue other strategies.